Financial Times: India spurns Gilead over hepatitis C patent
“India’s patent controller has rejected a patent application from Gilead Sciences for a key compound for its blockbuster hepatitis C drug Sovaldi, a refusal that activists said would allow Indian companies immediately to start producing cheap generic versions of the medicine…” (Kazmin/Ward, 1/14).

Reuters: India rejects Gilead’s Hepatitis C drug patent request
“…The application had been opposed by Indian generic drugmaker Natco Pharma Ltd and New York-based Initiative for Medicines, Access & Knowledge (I-MAK) on the grounds that the drug, chemically called sofosbuvir, is not inventive enough compared with a previous formulation, according to patent office order documents seen by Reuters on Wednesday…” (Chatterjee, 1/14).